CORKEY BRITTON KENNETH,ELZEIN ELFATIH,JIANG ROBERT H.,KALLA RAO V.,KOLTUN DMITRY,LI XIAOFEN,MARTINEZ RUBEN,PARKHILL ERIC Q.,PERRY THAO,ZABLOCKI JEFF,VENKATARAMANI CHANDRASEKAR,GRAUPE MICHAEL,GUERRERO
申请号：
NZ61869112
公开号：
NZ618691A
申请日:
2012.06.29
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
The disclosure relates to compounds of formula IA that are sodium channel inhibitors, wherein Q, Cy, R2 &ndash R4, R17, R10, m and n are as described in the specification. The disclosure also relates to their use the treatment of various disease states, including cardiovascular diseases and diabetes. The cardiovascular disease may be atrial and ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal&rsquos (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension or intermittent claudication. Example compounds include: (S)-3-methyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-S(2H)-one, (R)-3-methyl-4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-S(2H)-one, 6-((S-oxo-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)methyl)picolinonitrile, 7-(4-(trifluoromethoxy)phenyl)-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)-3,4-dihydrobenzo[f][I,4]oxazepin-5(2H)-one, 7-(4-(trifluoromethoxy)phenyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one, 4-((6-methylpyridin-2-yl)methyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one, (2R,11aS)-2-amino-7-(4-(trifluoromethyl)phenyl)-2,3,11,11a-tetrahydrobenzo[f]pyrrolo[2,1-c][1,4]oxazepin-5(1H)-one, (R)-2-(2,2-difluoroethyl)-8-(4-(trifluoromethyl)phenyl)-3,4,12,12a-tetrahydro-1Hbenzo[f]pyrazino[2,1-c][1,4]oxazepin-6(2H)-one.
